concentration within intracellular stores is not known, nor is the biochemical machinery that mediates the signaling from Ca 2ϩ stores to the plasma membrane.In this study, we demonstrate that overexpression of calreticulin in L fibroblasts leads to an increase in the Ca 2ϩ content of thapsigargin-sensitive Ca 2ϩ stores and to a decrease in store-operated Ca 2ϩ influx.
EXPERIMENTAL PROCEDURESMaterials-Thapsigargin and Geneticin were obtained from Life Technologies (Basel, Switzerland); monensin, ionomycin, and DTPA were obtained from Sigma. 45 Ca 2ϩ was purchased from Du Pont de Nemours/New England Nuclear Inc. (Dreieich, Germany), and fura-2/AM was from Molecular Probes, Inc. (Eugene, OR). Dulbecco's modified Eagle's culture medium and fetal calf serum were obtained from Gibco (Paisley, Scotland). Restriction endonucleases and DNA-modifying enzymes were purchased from Boehringer Mannheim, Life Technologies, Inc., and Bio/Can Scientific. Mouse L fibroblasts were a generous gift of D. Kobasa (Department of Biochemistry, University of Alberta). All other chemicals were of the highest grade available and were obtained from Fluka (Buchs, Switzerland) or Sigma. The medium referred to as "Ca 2ϩ -free medium" contained 138 mM NaCl, 6 mM KCl, 1 mM MgCl 2 , 20 mM glucose, and 20 mM HEPES, pH 7.4. The medium referred to as "Ca 2ϩ medium" contained, in addition, 1.0 mM CaCl 2 . When drugs were added as dimethyl sulfoxide solutions, final concentrations of dimethyl sulfoxide in the recording medium did not exceed 0.25%.Plasmid Construction-To construct pRCR calreticulin expression vector, the DraI/SmaI restriction DNA fragment (nucleotides 20 -1653) of pcDx-CRT (GenBank accession number J05138) (4) was first inserted into SmaI-digested pSVL vector (Pharmacia Biotech Inc.) to generate pSVL-CRT (pSCR-1) calreticulin expression vector. Next, the XhoI/SstI DNA restriction fragment, containing cDNA encoding full-length calreticulin, was excised from pSCR-1 vector and inserted into XhoI/SstI restriction sites of pRc/CMV vector (Invitrogen) to generate pRCR. * This work was supported by Swiss National Foundation Grant 32 30161.90 and by grants from the Medical Research Council of Canada, the Carlos and Elsie de Reuter Foundation, the Sandoz Foundation, the Ernst and Lucie Schmidheiny Foundation, the Société Académique de Genève, the Helmut Horten Foundation, and the Zyma Foundation. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.§ To whom correspondence should be addressed.